Clinical Trials | Mills Clinical Research

Currently Enrolling

Below is a list of studies that we will either be soon enrolling or that we are currently enrolling for at Mills Clinical Research.

They include studies on and for the following:

  • New HIV medications
  • People looking to switch HIV medications

Interested? Call 310-550-2271 to speak to the study coordinator.

New HIV Medications and People Looking to Switch HIV Medications

Study: TANGO

Title: A Phase III, randomized, multicenter, parallel-group, non-inferiority study evaluating the efficacy, safety, and tolerability of switching to dolutegravir plus lamivudine in HIV-1 infected adults who are virologically suppressed.

Study: ATLAS 2M

Title: Study Evaluating the Efficacy, Safety, and Tolerability of Long-acting Cabotegravir Plus Long-acting Rilpivirine administered every 8 weeks in Virologically Suppressed HIV-1-infected Adults

Study: TMB-311

Title: A Phase 3, Multicenter, Expanded Access Study of Ibalizumab Plus an Optimized Background Regimen (OBR) in Treatment-Experienced Patients Infected With Multi-Drug Resistant (MDR) HIV-1

Study: GS-US-382-3961

Title: A Phase 1b, Randomized, Double-Blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of GS-9620 in Antiretroviral Treated HIV-1 Infected Controllers

Study: GS-US-382-1450

Title: A Phase 1b, Randomized, Blinded, Placebo-Controlled Dose-Escalation Study of the Safety and Biological Activity of GS-9620 in HIV-1 Infected, Virologically Suppressed Adults

Study: COH 14017

Title: A Pilot Study to Evaluate the Feasability, Safety and Engraftment of Zinc Finger Nucleases (ZFN) CCR5 Modified CD34+ Hematopoietic Stem/Progenitor Cells (SB-728MR-HSPC) in HIV-1 (R5) Infected Patients

Study: Bio 001

Title: Studies on the Biology and Treatment of Multiple Myeloma, Other Plasma Cell Dyscrasias, Lymphoma, B-Cell Tumors, Other cancers, Immunodeficiency, and Autoimmune diseases

HIV Pre-Exposure Prophylaxis

Study: Priapus2

Title: A Single-center, Single-Arm, Open-Label, 48-Week Study of 60 Patients Prescribed PrEP at the Southern California Men’s Medical Group

Interested? Call 310-550-2271 to speak to the study coordinator.